微博
加入微博一起分享新鲜事
登录
|
注册
140
Atezolizumab, bevacizumab, pemetrexed and platinum for <i>EGFR</i>-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis https://journal.hep.com.cn/ctm/EN/10.1002/ctm2.70149
请登录并选择要私信的好友
300
Atezolizumab, bevacizumab, pemetrexed and platinum for <i>EGFR</i>-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis https://journal.hep.com.cn/ctm/EN/10.1002/ctm2.70149
赞一下这个内容
公开
分享
获取分享按钮
正在发布微博，请稍候